Virologist spoke about the pros and cons of an intravenous drug from COVID-19

Virologist Netesov about Areplivir: an intravenous drug acts faster than tablets on the pros and cons of the domestic intravenous candidate antiviral drug used for COVID-19.

Earlier it became known that the first domestic injectable drug for the treatment of direct-acting coronavirus was registered in Russia. It is called “Areplivir” (international non-proprietary name “Favipiravir” – approx. “Lenta.ru” ) and will be admitted to hospitals by the end of 2021.

that when you take a pill, it begins to act in about an hour or two due to the fact that it has to get into the stomach and intestines, dissolve, seep through the walls, and only after that it starts to do its job. The drugs that are administered intravenously act almost immediately, as they enter the bloodstream and quickly spread throughout the body, “Netesov spoke about the advantages of the intravenous drug.

However, the virologist noted that there are questions about this drug, since “Favipiravir” is a Japanese development, and at home it is not used to treat COVID-19. “Honestly, I am surprised how it got spread in our country, when in the homeland of this drug it is not used to treat COVID-19, and Japan is far from a backward country. If something has been checked there, then it is reliable, “the biologist emphasized.

Comments

comments